BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vorinostat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vorinostat\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06145633-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Vorinostat: Phase 2 readout est. (NCT06145633)
DESCRIPTION:Vorinostat\, phase 2.\nStudy: Vorinostat and 177Lu-PSMA-617 for
  the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
 \nEstimated primary completion: 30 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/vorinostat#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06145633
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04308330-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vorinostat: Phase 1 readout est. (NCT04308330)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: Vorinostat in Combination With Ch
 emotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vorinostat#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04308330
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150026-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vorinostat: Phase 1 readout est. (NCT07150026)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: An Exploratory Evaluation of the 
 Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/vorinostat#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07150026
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150013-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vorinostat: Phase 1 readout est. (NCT07150013)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: Rett REVOLUTION Trial: An Explora
 tory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vorinostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07150013
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00392353-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vorinostat: Phase 1/2 readout est. (NCT00392353)
DESCRIPTION:Vorinostat\, phase 1/2.\nStudy: Vorinostat and Azacitidine in T
 reating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia\
 nEstimated primary completion: 31 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vorinostat#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT00392353
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01587352-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vorinostat: Phase 2 readout est. (NCT01587352)
DESCRIPTION:Vorinostat\, phase 2.\nStudy: Vorinostat in Treating Patients W
 ith Metastatic Melanoma of the Eye\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vorinostat#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0158
 7352
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317403-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vorinostat: Phase 1 readout est. (NCT05317403)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: Venetoclax to Augment Epigenetic 
 Modification and Chemotherapy\nEstimated primary completion: January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/vorinostat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05317403
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06693284-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Vorinostat: Phase 1 readout est. (NCT06693284)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: A Window of Opportunity Trial of 
 Mirdametinib Plus Vorinostat for NF1 Associated\, H3K27 Trimethylation Def
 icient Malignant Peripheral Nerve Sheath Tumor [MPNST]\nEstimated primary 
 completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/vorinostat#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06693284
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01297764-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vorinostat: Phase 1/2 readout est. (NCT01297764)
DESCRIPTION:Vorinostat\, phase 1/2.\nStudy: A Study of Carfilzomib\, Lenali
 domide\, Vorinostat\, and Dexamethasone in Relapsed and/or Refractory Mult
 iple Myeloma\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vorinostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT01297764
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03843528-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Vorinostat: Phase 1 readout est. (NCT03843528)
DESCRIPTION:Vorinostat\, phase 1.\nStudy: Vorinostat Dose-escalation After 
 Allogeneic Hematopoietic Cell Transplantation\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vori
 nostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03843528
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995521-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Vorinostat: Phase 2 readout est. (NCT06995521)
DESCRIPTION:Vorinostat\, phase 2.\nStudy: Vorinostat for Graft-versus-host 
 Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AY
 A) Population\nEstimated primary completion: September 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/vorinostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06995521
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Vorinostat: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Vorinostat\, phase 1/2.\nStudy: TINI 2: Total Therapy for Infan
 ts With Acute Lymphoblastic Leukemia II\nEstimated primary completion: Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vorinosta
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 848687
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02559778-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Vorinostat: Phase 2 readout est. (NCT02559778)
DESCRIPTION:Vorinostat\, phase 2.\nStudy: Pediatric Precision Laboratory Ad
 vanced Neuroblastoma Therapy\nEstimated primary completion: September 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/vorinostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT02559778
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261241-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Vorinostat: Phase 2 readout est. (NCT07261241)
DESCRIPTION:Vorinostat\, phase 2.\nStudy: NANT 2021-02: Randomized MIBG Wit
 h Vorinostat/Dinutuximab/Vorinostat + Dinutuximab\nEstimated primary compl
 etion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/vorinostat#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07261241
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03167437-2027@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:Vorinostat: Phase 1/2 readout est. (NCT03167437)
DESCRIPTION:Vorinostat\, phase 1/2.\nStudy: An Open-Label\, Proof of Consen
 t Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Dise
 ase and Maintenance Therapy With Ustekinumab\nEstimated primary completion
 : 30 June 2035. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vorin
 ostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03167437
URL:https://assetmemo.bio/drug/vorinostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
